CONSOLIDATED RESULTS FOR ANNOUNCEMENT TO THE MARKET

For the half year ended 31 December 2014

Ellex Medical Lasers Limited ACN 007 702 927

This results announcement is to be read in conjunction with the statutory financial statements attached to this announcement.

Consolidated Results

				\$A'000
Revenues from ordinary activities	Up	19%	То	30,691
Consolidated results Earnings before interest, tax, depreciation and amortisation (EBITDA)	Up	93%	to	2,702
Profit for the period, before tax	Up	98%	to	1,293
Profit from ordinary activities after tax	Up	108%	to	815
Net profit for the period attributable to members	Up	108%	to	815
Dividends (distributions)	Amou secu			d amount per ecurity
Final Dividend				
Interim Dividend	Nil		Nil	
Previous corresponding period	N	il		Nil
Record date for determining entitlements to the dividend	NOT APPLICABLE			Е

OTHER INFORMATION

For the half year ended 31 December 2014

Ellex Medical Lasers Limited ACN 007 702 927

Net Tangible Assets per Security	Half Year ended 31 December 2014	Half Year ended 31 December 2013
Net tangible asset backing per ordinary security* (excludes value attributable to goodwill, other intangible assets, deferred tax asset, capitalised development expenditure and related deferred grant income)	\$0.17	\$0.20

Dividends

Date the dividend (distribution) is payable

NOT APPLICABLE

Record date to determine entitlements to the dividend (distribution)

NOT APPLICABLE

If it is a final dividend, has it been declared?

NOT APPLICABLE

Amount per security

	Amount per security	Franked amount per security at 30% tax	Amount per security of foreign source dividend
Final dividend:			
Current year	0.00 ¢	0.00 ¢	0.00 ¢
Previous year	0.00 ¢	0.00 ¢	0.00 ¢
Interim dividend:			
Current year	0.00 ¢	0.00 ¢	0.00 ¢
Previous year	0.00 ¢	0.00 ¢	0.00 ¢

Ellex Medical Lasers Limited ACN 007 702 927 Report for the half-year ended 31 December 2014

Contents	Page
Directors' report	2
Auditor's independence declaration	3
Consolidated statement of profit or loss and other comprehensive income	4
Consolidated statement of financial position	5
Consolidated statement of changes in equity	6
Consolidated statement of cash flows	7
Notes to the Consolidated financial statements	8
Directors' declaration	11
Independent auditor's review report	12
Corporate Directory	14

Directors' report

The directors of Ellex Medical Lasers Limited (The Company and the Group) submit herewith the financial report of Ellex Medical Lasers Limited and its subsidiaries (the Group) for the half-year ended 31 December 2014. In order to comply with the provisions of the Corporations Act 2001, the directors report as follows:

The names of the directors of the Company during or since the end of the half-year are:

Name

Mr V Previn Chairman

Mr A Sundich
Mr G Canala
Mon-Executive Director
Mr Rahmon Coupe
Non-Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

Ms Maria Maieli Company Secretary

Principal Activities

The principal activities of the Company during the course of the financial period were the manufacture, service and sale of ophthalmic equipment.

There were no significant changes in the nature of the activities of the company during the period.

Review of operations

Ellex Medical Lasers Limited (Ellex) generated a Net Profit After Tax of \$815 thousand for the half-year ended 31 December 2014 (2013: a Net Profit After Tax of \$391 thousand) on revenue of \$30,691 thousand (2013: \$25,883 thousand).

Auditor's independence declaration

The auditor's independence declaration is included on page 3 of the half-year report.

Rounding of amounts

The company is a company of the kind referred to in ASIC Class Order 98/100 and in accordance with that Class Order amounts in the directors' report and the half-year financial report are rounded off to the nearest thousand dollars, unless otherwise indicated.

Signed in accordance with a resolution of directors made pursuant to s.306 (3) of the Corporations Act 2001.

On behalf of the Directors

Victor Previn Chairman

Adelaide, 25 February 2014

Auditor's independence declaration to the members of Ellex Medical Lasers Limited



Level 1, 67 Greenhill Rd Wayville SA 5034

Correspondence to: GPO Box 1270 Adelaide SA 5001

T 61 8 8372 6666 F 61 8 8372 6677 E info.sa@au.gt.com Wwww.grantthornton.com.au

AUDITOR'S INDEPENDENCE DECLARATION TO THE DIRECTORS OF ELLEX MEDICAL LASERS LIMITED

In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of Ellex Medical Lasers Limited for the half-year ended 31 December 2014, I declare that, to the best of my knowledge and belief, there have been:

- a No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- b No contraventions of any applicable code of professional conduct in relation to the review.

Grant Thornton

GRANT THORNTON AUDIT PTY LTD Chartered Accountants

Adelaide, 25 February 2015

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.

Consolidated statement of profit or loss and other comprehensive income for the half-year ended 31 December 2014

Consolidated Group

	Note	Half-year ended 31 Dec 2014 \$'000	Half-year ended 31 Dec 2013 \$'000
Revenue		30,691	25,883
Other income / (expenses)		32	57
Changes in inventories of finished goods and work in progress		621	240
Raw materials and consumables used		(14,997)	(12,906)
Employee benefits expense		(8,328)	(7,570)
Depreciation and amortisation expense		(1,322)	(608)
Facilities expenses		(1,140)	(819)
Legal costs		(237)	(159)
Advertising and marketing expense		(1,701)	(814)
Finance costs Product development raw materials and consumables used		(87) (352)	(141) (199)
Realised foreign exchange gain/(loss)		(352) 521	(199) (475)
Other expenses		(2,408)	(1,835)
Other expenses		(2,400)	
Profit before tax		1,293	654
Income tax benefit/(expense)		(478)	(263)
Profit for the period		815	391
Other comprehensive income Items that may be reclassified subsequently to profit or loss (tax:nil)			
Exchange differences on translating foreign operations		510	(316)
Total comprehensive income for the period		1,325	75
F		-,	
Earnings per share:			
From continuing operations:			
Basic (cents per share)		0.75	0.36
Diluted (cents per share)		0.75	0.43
Dilated (conto per criare)		0.73	0.40

Consolidated statement of financial position as at 31 December 2014

Consolidated Group

Current assets 30 June 2014 2014 5000 Cash and cash equivalents 3,899 1,768 Cash and cash equivalents 11,222 11,805 Current inventories 16,496 14,172 Other current assets 916 14,412 Other current assets 916 1,412 Trade and other receivables 156 218 Trade and other receivables 1,937 1,464 Non-current inventories 1,937 1,464 Property, plant and equipment 3,141 3,078 Captialised development expenditure 10,150 9,682 Other intangible assets 3,342 2,833 Deferred tax assets 5,334 6,796 Total assets 5,933 54,228 Current liabilities 7,173 5,889 Trade and other payables 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 26 83 Total current liabilities 16,159 <th></th> <th></th> <th></th>			
Cash and cash equivalents 3,899 1,768 Trade and other receivables 11,222 11,805 Current inventories 16,496 14,172 Other current assets 916 1,412 Total current assets 32,533 29,157 Non-current assets 32,533 29,157 Non-current inventories 156 218 Non-current inventories 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 3,742 3,833 Deferred tax assets 6,334 6,796 Other intangible assets 57,993 54,228 Current liabilities 7,173 5,889 Total assets 57,993 54,228 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 25 83 Total current liabilities 16,159	Note	2014	2014
Trade and other receivables 11,222 11,805 Current inventories 16,496 14,172 Other current assets 32,533 29,157 Total current assets 32,533 29,157 Non-current assets 156 218 Trade and other receivables 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 6,334 6,796 Total assets 6,334 6,796 Total assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities 7,173 5,889 Trade and other payables 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Borrowings 2631 2,631	Current assets		
Trade and other receivables 11,222 11,805 Current inventories 16,496 14,172 Other current assets 32,533 29,157 Total current assets 32,533 29,157 Non-current assets 156 218 Trade and other receivables 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 6,334 6,796 Total assets 6,334 6,796 Total assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities 7,173 5,889 Trade and other payables 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Borrowings 2631 2,631	Cash and cash equivalents	3,899	1,768
Other current assets 916 1,412 Total current assets 32,533 29,157 Non-current assets 156 218 Trade and other receivables 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,155 9,682 Other intangible assets 3,742 3,833 Deferred tax assets 6,334 6,796 Total non-current assets 55,993 54,228 Current liabilities 57,993 54,228 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provision for income 525 389 Provision for income tax 28 3 Trade and other payables 16,159 13,873 Non-current liabilities 16,159 13,873 Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 3 Trade and other payables 2,631	Trade and other receivables	11,222	11,805
Total current assets 32,533 29,157 Non-current assets 1 6 218 Trade and other receivables 1,937 1,464 Non-current inventories 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 6,334 6,793 Deferred tax assets 6,334 6,796 Total non-current assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 3,559 3,405	Current inventories	16,496	14,172
Non-current assets 156 218 Trade and other receivables 1,937 1,464 Non-current inventories 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 6,334 6,796 Deferred tax assets 6,334 6,796 Total non-current assets 57,993 54,228 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Tade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 <td>Other current assets</td> <td>916</td> <td>1,412</td>	Other current assets	916	1,412
Trade and other receivables 156 218 Non-current inventories 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 3,742 3,833 Deferred tax assets 6,334 6,796 Total non-current assets 25,460 25,071 Total assets 7,173 5,889 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 38 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 782 605 Deferred income 52 47 P	Total current assets	32,533	29,157
Non-current inventories 1,937 1,464 Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 3,742 3,833 Deferred tax assets 6,334 6,796 Total non-current assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities 7,173 5,889 Trade and other payables 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 782 605 Deferred income 52 47 <	Non-current assets		
Property, plant and equipment 3,141 3,078 Capitalised development expenditure 10,150 9,682 Other intangible assets 3,742 3,833 Deferred tax assets 6,334 6,796 Total non-current assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 2,631 Trade and other payables 2,631 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 3,559 3,405 Total non-current liabilities 3,559 3,405 Total inon-current liabilities 19,718 17,278 Net assets <	Trade and other receivables	156	218
Capitalised development expenditure 10,150 9,682 Other intangible assets 3,742 3,833 Deferred tax assets 6,334 6,796 Total non-current assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities Trade and other payables Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 2,631 Deferred income 52 47 Provisions 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity 18 41,229 41,229	Non-current inventories	1,937	1,464
Other intangible assets 3,742 3,833 Deferred tax assets 6,334 6,796 Total non-current assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,621) (2,148)	Property, plant and equipment	3,141	3,078
Deferred tax assets 6,334 6,796 Total non-current assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities Trade and other payables 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 2,631 Borrowings 782 605	Capitalised development expenditure	10,150	9,682
Total non-current assets 25,460 25,071 Total assets 57,993 54,228 Current liabilities Trade and other payables 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total ilabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Other intangible assets	3,742	3,833
Total assets 57,993 54,228 Current liabilities 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity 18sued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,621) (2,131)	Deferred tax assets	6,334	6,796
Current liabilities Trade and other payables 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Total non-current assets	25,460	25,071
Trade and other payables 7,173 5,889 Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Total assets	57,993	54,228
Borrowings 5,593 5,137 Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Current liabilities		
Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 782 605 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Trade and other payables	7,173	5,889
Provisions 2,843 2,375 Deferred income 525 389 Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 782 605 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Borrowings	5,593	5,137
Provision for income tax 25 83 Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity 19,718 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)		2,843	2,375
Total current liabilities 16,159 13,873 Non-current liabilities 2,631 2,631 Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Deferred income	525	389
Non-current liabilities Trade and other payables Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Provision for income tax	25	83
Trade and other payables 2,631 2,631 Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Total current liabilities	16,159	13,873
Borrowings 782 605 Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Non-current liabilities		
Deferred income 52 47 Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Trade and other payables	2,631	2,631
Provisions 94 122 Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity 19,718 11,278 Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Borrowings	782	605
Total non-current liabilities 3,559 3,405 Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity 19,718 17,278 Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Deferred income	52	47
Total liabilities 19,718 17,278 Net assets 38,275 36,950 Equity \$\$\$Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Provisions	94	122
Net assets 38,275 36,950 Equity 38,275 36,950 Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Total non-current liabilities	3,559	3,405
Equity 41,229 41,229 Issued capital 41,229 (2,131) Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Total liabilities	19,718	17,278
Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Net assets	38,275	36,950
Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)			
Issued capital 41,229 41,229 Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)	Equity		
Reserves (1,621) (2,131) Accumulated losses (1,333) (2,148)		41,229	41,229
Accumulated losses (1,333) (2,148)	•		(2,131)
	Accumulated losses		
	Parent entity interest	38,275	

Consolidated statement of changes in equity for the half-year ended 31 December 2014

	Issued Capital \$'000	Other Reserve \$'000	Foreign Currency Reserve \$'000	Accumu- lated Losses \$'000	Total \$'000
Balance at 1 July 2013 Total comprehensive income for the period Shares issued during period Transaction costs	35,188 - 6,312 (374)	142 - -	(1,565) (316) - -	(2,936) 391 - -	30,829 75 6,312 (374)
Subtotal Dividends paid or provided for	41,126 -	142 -	(1,881) -	(2,545)	36,842
Balance at 31 December 2013	41,126	142	(1,881)	(2,545)	36,842
Balance at 1 July 2014 Total comprehensive income for the period Shares issued during period Transaction costs	41,229 - - -	142 - -	(2,273) 510 - -	(2,148) 815 - -	36,950 1,325 -
Subtotal Dividends paid or provided for	41,229 -	142 -	(1,763) -	(1,333) -	38,275
Balance at 31 December 2014	41,229	142	(1,763)	(1,333)	38,275

Consolidated statement of cash flows for the half-year ended 31 December 2014

Consolidated Group

		Half-year ended 31 Dec 2014	Half-year ended 31 Dec 2013
Not	e	\$'000	\$'000
Cash flows from operating activities Receipts from customers Grant Income Payments to suppliers and employees Interest and other costs of finance paid Income tax paid		31,086 46 (28,398) (87) (72)	25,566 - (23,966) (141) (112)
Net cash provided by operating activities		2,575	1,347
Cash flows from investing activities Payment for acquisition of business assets Payment for property, plant and equipment Payment for intangible assets Payment for capitalised development costs Interest received		(245) (96) (1,242)	(1,681) (86) (24) (827) 3
Net cash used in investing activities		(1,583)	(2,615)
Cash flows from financing activities Proceeds from issues of equity Payment for share issue costs Proceeds from borrowings Repayment of borrowings Repayment of leases		1,182 (553) (9)	6,312 (374) (1,224) (6)
Net cash (used in)/provided by financing activities		620	4,708
Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at the beginning of the period Effects of exchange rate changes on the balance of cash held in foreign currencies Cash and cash equivalents at the end of the period		1,612 1,786 (369) 3,029	3,440 (513) 30 2,957

Ellex Medical Lasers Limited

Notes to the Consolidated financial statements for the half-year ended 31 December 2014

Notes to the Consolidated financial statements for the half-year ended 31 December 2014

Note 1: Basis of preparation

These general purpose financial statements for the interim half-year reporting period ended 31 December 2014 have been prepared in accordance with requirements of the Corporations Act 2001 and Australian Accounting Standards including AASB 134: Interim Financial Reporting. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Ellex Medical Lasers Limited and its controlled entities (the Group). As such, it does not contain information that represents relatively insignificant changes occurring during the half-year within the Group. It is therefore recommended that this financial report be read in conjunction with the annual financial statements of the Group for the year ended 30 June 2014, together with any public announcements made during the half-year.

The interim financial statements have been prepared in accordance with the accounting policies adopted in the Group's last annual financial statements for the year ended 30 June 2014, except for the application of the following standards as of 1 July 2014:

AASB 1031: materiality

AASB 1055: Budgetary reporting

AASB 2013-1, Amendments to AASB 1049- Relocation of Budgetary Reporting Requirements

AASB 2013-4, Novation of Derivatives and Continuation of Hedge Accounting

AASB 2013-5, Investment entities

AASB 2013-9, Conceptual Framework, materiality and financial instruments

AASB 2014-2, Amendments to AASB 1053- Transition to and between tiers, and related tier 2 disclosure requirements

AASB 2014-1, Amendments to Australian Accounting Standards Part A, B and C

These standards make changes to a number of existing Australian Accounting Standards and are not expected to result in a material change to the manner in which the Group's financial result is determined or upon the extent of disclosures included in future financial reports. Management has reviewed the new requirements of the above standards and has concluded that there is no effect on the classification or presentation of balances.

The accounting policies have been applied consistently throughout the Group for the purpose of preparation of these interim financial statements.

Management has reviewed the new requirements of the above standards and has concluded that there is no effect on the classification or presentation of balances as the group has no arrangements within the scope of the above standards.

Estimates

When preparing the interim financial statements, management undertakes a number of judgments, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgments, estimates and assumptions made by management, and will seldom equal the estimated results. The judgments, estimates and assumptions applied in the interim financial statements, including the key source of estimate uncertainty were the same as those applied in the Group's last annual financial statements for the year ended 30 June 2014.

Note 2: Commitments

An amount of \$99,155 is added to the commitments set out in the 30 June 2014 accounts. This represents commitment on a new property lease.

Note 3: Contingencies

There has been no change in contingent liabilities since the last annual reporting period.

Note 4: Events occurring After the Interim Period

No matters or circumstances have arisen since the end of the half hear which significantly affected or could significantly affect the operations, of the Group, the results of the operations or the state of affairs of the Group in the future financial years.

Note 5: Operating Segments

(I) Segment performance	Distributors \$'000	Direct \$'000	Total \$'000
Six months ended 31 December 2014 Revenue			
External sales	7,886	22,805	30,691
Total segment revenue	7,886	22,805	30,691
Segment net profit before tax	3,190	3,543	6,733
Reconciliation of segment result to group net profit/(loss) before tax Amounts not included in segment result: Depreciation and amortisation Unallocated items: Corporate costs, quality and service charges			(1,322) (4,031)
Finance costsInterest revenue		_	(87)
Net profit before tax from continuing operations		_	1,293
	Distributors \$'000	Direct \$'000	Total \$'000
Six months ended 31 December 2013			
Revenue External sales	6,365	19,518	25,883
Total segment revenue	6,365	19,518	25,883
Segment net profit before tax	1,797	2,475	4,272
Reconciliation of segment result to group net profit/(loss) before tax Amounts not included in segment result: Depreciation and amortisation			(608)
Unallocated items:			(2,871)
Cornorate costs, quality and service charges			
 Corporate costs, quality and service charges Finance costs Interest revenue 			(141) 2

(ii) Segment assets			
	Distributors \$'000	Direct \$'000	Total \$'000
31 December 2014			
Segment assets - opening	15,059	18,858	33,917
Segment asset changes for the period: Net reduction in inventories and receivables	1,505	2,594	4,099
Total segment assets	16,564	21,452	38,016
		21,432	30,010
Reconciliation of segment assets to group assets Inter-segment eliminations			
Unallocated assets:			
Deferred tax assets			6,334
Capitalised development expenditureIntangibles			10,150 3,742
·			
Total group assets		_	58,242
30 June 2014			
Segment assets – opening	7,531	23,634	31,165
Segment asset changes for the period: Net reduction in inventories and receivables	7.500	(4.770)	0.750
Net reduction in inventories and receivables	7,528	(4,776)	2,752
Total segment assets	15,059	18,858	33,917
Reconciliation of segment assets to group assets			
Inter-segment eliminations Unallocated assets:			
Deferred tax assets			6,796
Capitalised development expenditure			9,682
Intangibles		_	3,833
Total group assets		_	54,228

Note 6: Reconciliation of cash and cash equivalents.

	Half-year ended 31 Dec 2014 \$'000	Half-year ended 31 Dec 2013 \$'000
Cash and cash equivalents	3,899	2,957
Bank overdraft	(870)	-
	3,029	2,957

Directors' declaration

Directors' declaration

The directors declare that:

- (a) The financial statements and notes are in accordance with the corporations Act 2001, including:
 - complying with Accounting Standard 134 "Interim Financial Reporting" and the Corporations Regulations 2001;
 - (ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date.
- (b) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and

Signed in accordance with a resolution of the directors made pursuant to s.303 (5) of the Corporations Act 2001.

On behalf of the Directors

Victor Previn Chairman

Adelaide, 25 February 2014

Directors' declaration

Independent auditor's review report to the members of Ellex Medical Lasers Limited



Level 1, 67 Greenhill Rd Wayville SA 5034

Correspondence to: GPO Box 1270 Adelaide SA 5001

T 61 8 8372 6666 F 61 8 8372 6677 Einfo.sa@au.gt.com Wwww.grantthornton.com.au

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF ELLEX MEDICAL LASERS LIMITED

We have reviewed the accompanying half-year financial report of Ellex Medical Lasers Limited ("Company"), which comprises the consolidated financial statements being the statement of financial position as at 31 December 2014, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a statement or description of accounting policies, other explanatory information and the directors' declaration of the consolidated entity, comprising both the Company and the entities it controlled at the half- year's end or from time to time during the half-year.

Directors' responsibility for the half-year financial report

The directors of Ellex Medical Lasers Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such controls as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the consolidated half-year financial report based on our review. We conducted our review in accordance with the Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the Ellex Medical Lasers Limited consolidated entity's financial position as at 31 December 2014 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of Ellex Medical Lasers Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Ltd ABN 41 127 556 389

'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Ltd is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 and its Australian subsidiaries and related entities. GTIL is not an Australian related entity to Grant Thornton Australia Limited.

Liability limited by a scheme approved under Professional Standards Legislation. Liability is limited in those States where a current scheme applies.



A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit.

Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Ellex Medical Lasers Limited is not in accordance with the Corporations Act 2001, including:

- a giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date; and
- b complying with Accounting Standard AASB 134 Interim Financial Reporting and Corporations Regulations 2001.

GRANT THORNTON AUDIT PTY LTD

Grant Thornton

Chartered Accountants

S K Edwards

Partner - Audit & Assurance Adelaide, 25

February 2015

Corporate Directory

Directors

Mr Victor Previn BE (Chairman)

Mr Alex Sundich BEc, MComm, ACA, FFINSIA (Non-Executive Director)

Mr Giuseppe Canala

BTECH, BA, FAICD (Non-Executive Director)

Mr Rahmon Coupe

BEng (Hons) (Non-Executive Director)

Dr Meera Verma

PhD, FTSE, FAICD (Non-Executive Director)

Company Secretary

Ms Maria Maieli MPAcc, CPA

Registered Office

Ellex Medical Lasers Limited ABN 15 007 702 927 82 Gilbert Street

Adelaide South Australia 5000 Telephone: +61 8 8104 5200 Facsimile: +61 8 8104 5231

Auditors

Grant Thornton Audit Pty Limited Level 1, 67 Greenhill Road Wayville South Australia 5034

Share Registry

Computershare Investor Services Limited Level 5, 115 Grenfell Street Adelaide South Australia 5000

GPO Box 1903

Adelaide South Australia 5001

Enquiries within Australia: 1300 556 161 Enquiries outside Australia: +61 3 9415 4000

Website: www.computershare.com

Websites:

www.ellex.com www.slt-ellex.com

Stock Exchange

The company Ellex Medical Lasers Limited is listed on the Australian Securities Exchange (ASX). The ASX Code is: ELX-Ordinary Shares.